ARTICLES BY YULIA PRIVOLNEV

• What’s A Cure Worth? ICER Publishes Value Assessment Framework For Curative Therapies

  8/27/2019

  The Institute for Clinical and Economic Review (ICER) recently conducted a study of value assessment methods considered for “cures” or “potential cures” and solicited input from international HTA bodies. The research will form the basis of a value framework that will be applied in the assessment of potential cures and other treatments that qualify as what ICER refers to as “single or short-term transformative therapies.”

• Pharma Industry Braces For A No-Deal Brexit

  3/22/2019

  Chaos reigns supreme in London at the moment, as British Prime Minister Theresa May struggles to find a graceful way for the United Kingdom to exit from the European Union (EU). Meanwhile, pharmaceutical manufacturers must prepare for multiple potential outcomes, including a “no-deal” (or “hard”) Brexit.

• CAR T-Cell Therapies In The EU5: What Can We Expect From Payers?

  1/24/2019

  The difficulty of balancing paying for innovation with budgets has plagued Europe for years, and the emergence of cell and gene therapies has only exacerbated that conundrum. 

• The Brexit Deal And Its Impact On The Pharmaceutical Industry

  11/30/2018

  According to trade groups, approximately 45 million packs of medicines leave the U.K. for Europe every month, and 37 million go in the opposite direction. In a year, that’s almost 1 billion packs of medicines. What those borders would look like after a Brexit deal would significantly impact major industries in the U.K. and EU economies.

• Brexit: The Good, The Bad, And The Chaos

  8/22/2018

  With just over half a year to go until the divorce date, and roughly two months until European Chief Brexit Negotiator Michel Barnier’s self-imposed October deadline for a Brexit deal, it has started to feel like we are finally seeing some concrete progress when it comes to Brexit.

• Unpacking The Latest Brexit Developments And Their Potential Impact On Pharma

  5/25/2018

  As the divorce date approaches for the U.K. and the EU, one would be forgiven for thinking there would be a plan in place to deal with an event that will have such a profound global impact on the pharma industry. However, manufacturers have to prepare for any possibly scenario, while continuing to wait for clarity.

• Should Pharma Companies Even Care About Brexit?

  1/29/2018

  It is difficult to assess the ultimate impact of Brexit on the pharmaceutical industry when so much remains unknown. However, many would argue it is exactly this uncertainty that makes Brexit so disruptive. 

• Preparing For Brexit: Advice From The EMA

  12/18/2017

  The U.K.’s Business, Energy and Industrial Strategy (BEIS) parliamentary committee announced it is investigating the implications of Brexit for the U.K.’s pharmaceutical market, amidst fears Brexit will threaten "the cost of medicines, investment in the United Kingdom and access to new and innovative research and products."

   

• What Is Pharmaceutical Innovation, Anyway? Italy’s New Algorithm & The Global Trend

  10/20/2017

  Innovation has long been a topic of focus in the pharmaceutical industry, with developers striving for it, regulators and payers demanding it. But, what exactly do we mean when we talk about “innovation”?

• Brexit’s Impact On The Global Pharmaceutical Industry: Future Access To The EU Common Market

  7/6/2016

  On June 23, 2016, the voters of the United Kingdom voted to leave the European Union in an advisory referendum colloquially referred to as the “Brexit” (British exit) vote. The aftermath of the vote has been chaotic — from financial troubles that have seen the British economy and currency plummet, to political bedlam that has led to a number of political casualties, including the Prime Minister and his heir apparent. While analysts, journalists, and the public all discuss the impact of Brexit on the UK and the path forward, few realize the implications that the vote will have on healthcare, and the pharmaceutical industry in particular.